行情

TMBR

TMBR

Timber Pharmaceuticals
AMEX
0.0949
-0.0251
-20.92%
盘后: 0.0960 +0.0011 +1.16% 19:59 10/03 EDT
开盘
0.0990
昨收
0.1200
最高
0.0990
最低
0.0826
成交量
1,632.73万
成交额
0
52周最高
0.9200
52周最低
0.0826
市值
1,256.96万
市盈率(TTM)
-0.2856
分时
5日
1月
3月
1年
5年
Timber Pharmaceuticals 推出 130 万美元的发行,计划反向股票拆分;股价下跌
Timber Pharmaceuticals 推出 130 万美元的发行,计划反向股票拆分;股价下跌
MT Newswires · 1天前
Timber Pharmaceuticals 收到欧洲关于皮肤病治疗孤儿指定的积极意见;股价上涨
Timber Pharmaceuticals 收到欧洲关于皮肤病治疗孤儿指定的积极意见;股价上涨
MT Newswires · 09/14 10:29
--HC Wainwright 将 Timber Pharmaceuticals 的目标价格从 1.50 美元调整至 1 美元,重申买入评级
--HC Wainwright 将 Timber Pharmaceuticals 的目标价格从 1.50 美元调整至 1 美元,重申买入评级
MT Newswires · 08/29 07:55
TMBR 简况
Timber Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of treatments for orphan dermatologic diseases. It is also focused on developing non-systemic treatments for rare dermatologic diseases, including congenital ichthyosis (CI), facial angiofibromas (FAs) in the tuberous sclerosis complex (TSC), and sclerotic skin diseases. Its lead mid to late-stage programs are TMB-001 and TMB-002. TMB-003 is its earliest stage program. TMB-001 is a topical formulation of isotretinoin using its IPEG delivery system, completed its Phase IIb clinical trials for the treatment of moderate to severe subtypes of CI. TMB-002 is a topical formulation of rapamycin, which is being evaluated in a Phase IIb clinical trial for the treatment of FAs in TSC. TMB-003 is a formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist for the treatment of sclerotic skin diseases.

微牛提供Timber Pharmaceuticals Inc(AMEX-TMBR)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的TMBR股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易TMBR股票基本功能。